Treatment of children with haemophilia in Europe: A survey of 20 centres in 16 countries

• A survey was made of the current status of treatment of haemophilic boys at 20 centres in 16 European countries and includes approximately 1500 of the estimated 6500 haemophiliacs in the participating countries. Many mild haemophiliacs are not seen, or seen infrequently, at haemophilia centres and this requires study. Nine of 18 centres provide continuous prophylaxis to 80-100% of their patients, five centres provide it to 55-80% and the remaining four centres to 15-40% of the boys. The median dose given was 6240 U kg-1 year-1 (range 3120-7800). Four centres administered only recombinant concentrates to children with severe haemophilia A, while seven centres administered recombinant concentrates to 75-90% and the remaining centres to less than 50% of the boys (two centres <10%). When asked for the choice of concentrate for a newly diagnosed boy with severe haemophilia A, all but one centre preferred recombinant concentrate. Most boys below 6 years received concentrates via a peripheral vein but three centres preferred a central venous line for 80-100% of the boys. Thirteen of 18 centres applied home treatment to 84-100% of the boys and the remaining five centres to 57-77% of the boys.

Nyckelord

Concentrate

Factor IX

Factor VIII

Haemophilia A.

Haemophilia B.

Prophylaxis

blood clotting factor 8

blood clotting factor 8 concentrate

blood clotting factor 9

blood clotting factor 9 concentrate

recombinant blood clotting factor 8

recombinant blood clotting factor 9

adolescent

adult

age

article

central venous catheterization

child

childhood disease

controlled study

disease severity

drug preference

drug response

Europe

health survey

hemophilia

hemophilia A

hemophilia B

home care

human

infant

major clinical study

male

multicenter study

peripheral vein

priority journal

Publikations- och innehållstyp

art (ämneskategori)

ref (ämneskategori)